Tasquinimod demonstrates potent anti-tumor activity in experimental models for multiple myeloma. Data will be presented at the Virtual Edition of the 25th European Hematology Association (EHA) Annual Congress Meeting, taking place June 11-21 2020

Inhibition of S100A9 with tasquinimod demonstrates potent anti-tumor activity in pre-clinical models of multiple myeloma. Cindy Lin , Aubrey Leso , Matthew Rosenwasser , Marie Torngren , Helena Eriksson , Yulia Nefedova. Presented at the Virtual Edition of the 25th European Hematology Association (EHA) Annual Congress Meeting, 2020. Read the abstract here and the poster here.